Filing Analysis
Gossamer Bio, Inc. has amended its Certificate of Incorporation to establish the rights and preferences of Series A-1 Convertible Preferred Stock. This action follows a previously announced private placement closing on August 24, 2026.
🚩 Red Flags
- Issuance of convertible preferred stock often indicates a need for immediate capital, potentially dilutive to existing common shareholders.
📋 Key Facts
- Amended Certificate of Incorporation filed with the Secretary of State of Delaware on August 24, 2026.
- Creation of Series A-1 Convertible Preferred Stock.
- The amendment is in connection with a previously announced private placement.
- The filing incorporates by reference the description of rights and preferences from an 8-K filed on August 21, 2026.
Gossamer Bio entered into a massive two-stage private placement agreement to raise up to $150 million (plus potential warrants) to fund the development of seralutinib. The deal is heavily contingent on FDA acceptance of an NDA and requires significant stockholder approval to issue the massive amount of underlying common stock.
🚩 Red Flags
- Massive potential dilution: The filing mentions issuance of hundreds of millions of shares (approx. 178M in first stage, 534M in FDA stage).
- Extreme low share price: The pricing ($0.14) suggests a highly distressed or micro-cap valuation context.
- Contingent financing: The second stage is dependent on FDA NDA acceptance, creating significant execution risk.
- Lock-up/Restriction: The company is prohibited from issuing other securities until the warrants/preferred stock are resolved.
📋 Key Facts
- Initial Closing (expected Aug 24, 2026): ~$25 million via pre-funded warrants at $0.1399/share.
- Second Closing (contingent on FDA NDA acceptance in 2026): ~$125 million via pre-funded warrants.
- FDA Approval Warrants: Potential for ~$100 million in additional proceeds if FDA approves seralutinib for PAH.
- Total potential gross proceeds: Approximately $250 million.
- Conversion prices for preferred stock range from $0.14 to $0.187 per share.
- The deal requires stockholder approval to issue the shares underlying the warrants/preferred stock.
Gossamer Bio, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2026. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2026.
- Filing date: August 13, 2026.
- The filing includes a press release as Exhibit 99.1 regarding results of operations and financial condition.
Gossamer Bio has entered into a Rights Reacquisition Agreement with Chiesi Farmaceutici S.p.A., effectively terminating their previous License Agreement and reacquiring worldwide development and commercial rights to seralutinib for PAH, PH-ILD, and other indications. The deal includes a $5 million reimbursement from Chiesi to Gossamer and involves complex milestone/royalty obligations in exchange for the asset return.
🚩 Red Flags
- Termination of a major collaboration agreement (License Agreement) suggests a pivot or strategic shift.
- Complexity of the reacquisition involves potential future royalty/milestone liabilities that could impact cash flow.
- The company's future performance is explicitly stated to be 'dependent entirely on the success of seralutinib'.
📋 Key Facts
- Entered into Rights Reacquisition Agreement with Chiesi Farmaceutici S.p.A. on July 23, 2026.
- Termination of the existing License Agreement dated May 3, 2024.
- Gossamer reacquires worldwide development and commercial rights to seralutinib (PAH, PH-ILD, etc.).
- Chiesi to pay Gossamer $5 million within 10 days as reimbursement for outstanding development costs.
- Gossamer will make success-based milestone payments and capped royalties to Chiesi.
- Company reported approximately $57.0 million in cash/equivalents as of June 30, 2026 (unaudited).
- Planned NDA submission for seralutinib in PAH is scheduled for September 2026.
Gossamer Bio, Inc. stockholders approved several major restructuring proposals at a special meeting on July 14, 2026, including an increase in authorized shares and a reverse stock split. The actions are primarily intended to facilitate the issuance of new convertible notes and warrants as part of an exchange offer.
🚩 Red Flags
- Approval of a reverse stock split (Red flag escalator).
- Massive increase in authorized shares (from 700M to 4B) indicates significant potential dilution for existing shareholders.
- The company is issuing 'New Convertible Senior Secured First Lien Notes due 2030' which typically carries high interest or heavy equity conversion components, suggesting urgent need for capital.
📋 Key Facts
- Stockholders approved a Charter Amendment increasing authorized Common Stock from 700 million to 4 billion shares.
- Stockholders approved a series of 30 alternate amendments to effect a reverse stock split and a proportionate reduction in authorized shares.
- The company successfully completed an exchange offer for $200.0 million in aggregate principal amount of 5.00% Convertible Senior Notes due 2027, which closed on June 4, 2026.
- Approval was granted for the potential issuance of shares upon conversion of up to $72.0 million in New Convertible Notes and the exercise of 135,789,000 Purchase Warrants.
- The Restated 2019 Incentive Award Plan was approved by stockholders.
Gossamer Bio, Inc. announced the conversion terms for its 7.50% Convertible Senior Secured First Lien Notes due 2030 and the exercise prices for associated purchase warrants.
🚩 Red Flags
- Extremely low conversion price ($0.19) suggests significant potential dilution for existing shareholders.
- Low share price context (implied by $0.19 conversion price) often indicates a distressed or highly speculative micro-cap profile.
- The use of 'Senior Secured First Lien' debt indicates the company is likely carrying high-cost, secured obligations.
📋 Key Facts
- Initial conversion rate for 2030 Convertible Notes: 5,347.5936 shares per $1,000 principal amount.
- Conversion price: approximately $0.19 per share of common stock.
- Initial exercise price of Purchase Warrants: $0.34 per whole share of common stock.
- The notes are 7.50% Convertible Senior Secured First Lien Notes due 2030.
Gossamer Bio, Inc. filed an 8-K to announce the release of its financial results for the quarter ended September 30, 2025.
📋 Key Facts
- The filing is a standard earnings announcement under Item 2.02.
- Financial results reported are for the quarter ending September 30, 2025.
- Press release containing detailed financial data is attached as Exhibit 99.1.
Gossamer Bio, Inc. entered into an Option Agreement and Plan of Merger with Prana Bio, Inc., granting the company the right to acquire Respira Therapeutics, Inc. via merger. The deal involves significant potential equity issuance through milestone-based payments.
🚩 Red Flags
- Significant potential dilution: Total potential share issuance related to this transaction could exceed 10.6 million shares (2.5M initial + 1.5M exercise + ~6.68M milestones).
📋 Key Facts
- Entered into an Option Agreement and Plan of Merger on September 24, 2025.
- Granted option to acquire Respira Therapeutics, Inc. from Prana Bio, Inc.
- Issued 2,500,000 shares of common stock as consideration for the merger option.
- Potential issuance of up to 1,500,000 additional shares upon exercise of the option.
- Contingent milestone payments include cash and up to ~6,688,964 additional shares based on regulatory and sales milestones.
Gossamer Bio, Inc. filed an 8-K to announce the release of its financial results for the quarter ended June 30, 2025.
📋 Key Facts
- The filing is a standard earnings announcement (Item 2.02).
- Reporting period: Quarter ended June 30, 2025.
- Report date: August 5, 2025.
- The full press release is attached as Exhibit 99.1.
Gossamer Bio, Inc. held its 2025 annual meeting of stockholders on June 25, 2025. The meeting resulted in the election of three directors and the ratification of several shareholder proposals, including the selection of Ernst & Young LLP as independent auditors.
🚩 Red Flags
- Significant 'Against' vote on the Amended and Restated 2019 Plan (41,469,393 votes against vs 87,795,419 for), indicating potential shareholder dissatisfaction with the new incentive structure.
📋 Key Facts
- Annual Meeting held on June 25, 2025.
- Stockholders approved the Amended and Restated 2019 Incentive Award Plan.
- Three Class I directors (Thomas Daniel, M.D., Sandra Milligan, M.D., J.D., and Steven Nathan, M.D.) were re-elected to three-year terms expiring in 2028.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Say-on-pay (executive compensation) was approved on an advisory basis.
Gossamer Bio, Inc. announced the completion of patient enrollment for its global Phase 3 PROSERA Study evaluating seralutinib for pulmonary arterial hypertension (PAH). The company expects to report topline results from this study in February 2026.
🚩 Red Flags
- None identified; this is a standard clinical milestone update for a biotech company.
📋 Key Facts
- Completed enrollment for the global registrational Phase 3 PROSERA Study.
- The study evaluates seralutinib in patients with Functional Class II and III pulmonary arterial hypertension (PAH).
- Phase 3 trial includes 390 participants, compared to 86 in the Phase 2 TORREY study.
- Topline results from the PROSERA Study are expected in February 2026.
- The study utilizes enrichment criteria including REVEAL Lite 2 Risk Score to optimize potential efficacy readout.
Gossamer Bio, Inc. filed an 8-K to announce the release of its financial results for the quarter ended March 31, 2025.
📋 Key Facts
- The filing is a routine announcement of quarterly earnings (Item 2.02).
- Reporting period: Quarter ended March 31, 2025.
- Filing date: May 15, 2025.
- The full press release is attached as Exhibit 99.1.
Gossamer Bio, Inc. filed an 8-K to announce the release of its financial results for the quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- Reporting period: Quarter and Fiscal Year ended December 31, 2024.
- Filing date: March 13, 2025.
- The filing includes a press release (Exhibit 99.1) detailing financial results.
Gossamer Bio, Inc. has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. This resolves the deficiency notice originally issued by Nasdaq on September 11, 2024.
🚩 Red Flags
- Historical non-compliance with Nasdaq listing requirements (minimum bid price) as of September 2024.
📋 Key Facts
- The Company received a letter from Nasdaq on February 19, 2025, confirming compliance with Nasdaq Listing Rule 5450(a)(1).
- The minimum bid price matter is now officially closed.
- The deficiency originated from the stock failing to maintain a $1.00 minimum price for 30 consecutive business days.
Gossamer Bio, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024. The filing serves as a formal announcement of the earnings release via press release.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2024.
- Filing date: November 7, 2024.
- The company issued a press release (Exhibit 99.1) containing the financial results.
Gossamer Bio received a notice from Nasdaq stating the company failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days between July 30, 2024, and September 10, 2024. The company has been granted a 180-day compliance period ending March 10, 2025.
🚩 Red Flags
- Delisting notice from Nasdaq
- Stock price has been below $1.00 for at least 30 consecutive business days
- Potential requirement for a reverse stock split to regain compliance
📋 Key Facts
- Received written notice from Nasdaq Listing Qualifications Department on September 11, 2024.
- Failure to meet the Minimum Bid Price Requirement (Nasdaq Listing Rule 5450(a)(1)).
- Compliance period expires March 10, 2025.
- To regain compliance, stock must close at $1.00 or higher for 10 consecutive business days before the deadline.
- Failure to comply may lead to a transfer to Nasdaq Capital Market or delisting.
Gossamer Bio, Inc. issued an 8-K to announce its financial results for the quarter ended June 30, 2024. The filing serves as a formal notification of the release of quarterly earnings via press release.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2024
- Report date: August 12, 2024
- The company issued a press release (Exhibit 99.1) containing the financial results.
- Signed by Bryan Giraudo, Chief Operating Officer and Chief Financial Officer.
Gossamer Bio, Inc. has received notification from Nasdaq confirming it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. This resolves a previous deficiency notice issued on May 22, 2024.
🚩 Red Flags
- Previous history of delisting risk due to low share price (minimum $1.00 requirement).
📋 Key Facts
- The Company has regained compliance with Nasdaq Listing Rule 5450(a)(1).
- The minimum bid price matter is now officially closed as of July 18, 2024.
- The previous non-compliance was due to the common stock failing to maintain a $1.00 minimum bid price for 30 consecutive business days.
Gossamer Bio, Inc. reported the results of its annual meeting of stockholders held on June 6, 2024. The meeting included the election of directors and advisory votes on auditor selection and executive compensation.
📋 Key Facts
- Skye Drynan was elected to serve as a Class II director for a three-year term expiring in 2027 (161,240,706 votes 'For').
- John Quisel, Ph.D., J.D., was elected to serve as a Class III director for a three-year term expiring in 2027 (161,260,707 votes 'For').
- Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Stockholders approved, on an advisory basis, the compensation of the Company's named executive officers (115,985,182 votes 'For').
Gossamer Bio received a notice from Nasdaq stating the company failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days between April 10, 2024, and May 21, 2024. The company has been granted a 180-day compliance period ending November 18, 2024.
🚩 Red Flags
- Delisting notice/non-compliance with minimum bid price requirement
- Potential necessity of a reverse stock split to regain compliance
- Risk of being moved from the Nasdaq Global Select Market to the Nasdaq Capital Market
📋 Key Facts
- Received written notice from Nasdaq Listing Qualifications Department on May 22, 2024.
- Failure to meet the $1.00 minimum bid price requirement (Nasdaq Listing Rule 5450(a)(1)).
- Compliance period expires on November 18, 2024.
- To regain compliance, stock must close at or above $1.00 for 10 consecutive business days before the deadline.
- Failure to comply may lead to a transfer to Nasdaq Capital Market or delisting.
Gossamer Bio, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024. The filing serves as a formal notification of the release of quarterly earnings data.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2024
- Report date: May 7, 2024
- The company issued a press release (Exhibit 99.1) containing the financial results.
- Signed by Bryan Giraudo, Chief Operating Officer and Chief Financial Officer.
Gossamer Bio entered into a global collaboration and license agreement with Chiesi Farmaceutici S.p.A to develop and commercialize seralutinib for PAH and PH-ILD. The deal includes significant upfront payments, milestones, and an equity option for Chiesi.
🚩 Red Flags
- Equity Option: Provides a potential dilutive mechanism via private placement if certain triggers (Phase 3 completion, tender offer, or change of control) occur.
- Concentration Risk: The company's financial upside is heavily tied to the success and commercialization efforts of a single partner (Chiesi).
📋 Key Facts
- Chiesi agreed to pay Gossamer $160 million as reimbursement for development costs.
- Gossamer is eligible for up to $146 million in regulatory milestones and $180 million in sales milestones.
- The agreement includes an 'Equity Option' allowing Chiesi to purchase shares at 107.5% of the 30-day VWAP (minimum $1.63/share) up to a 9.9% ownership stake.
- Gossamer will lead global development and US commercialization for PAH and PH-ILD, while sharing costs equally with Chiesi (except for the PROSERA Phase 3 study).
- The company successfully terminated its existing Credit Facility with MidCap Financial Trust as part of this transaction.
Gossamer Bio, Inc. announced the appointment of two new independent directors to its Board: Skye Drynan and Steven Nathan, M.D., effective March 11, 2024.
📋 Key Facts
- Skye Drynan appointed as Class III director; former Partner/Senior BioPharma Analyst at Capital Group.
- Steven Nathan, M.D. appointed as Class I director; Medical Director of Inova Health System’s Advanced Disease Program.
- Both directors will receive an annual cash retainer of $40,000.
- Each director was granted options to purchase 230,000 shares of common stock, vesting monthly over three years.
- The Board determined both appointees are independent per Nasdaq Global Select Market requirements.
Gossamer Bio, Inc. issued a press release on March 5, 2024, reporting its financial results for the quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- Reporting period: Quarter and Fiscal Year ended December 31, 2023.
- Report date: March 5, 2024.
- The filing is an announcement of earnings results via press release (Exhibit 99.1).
Gossamer Bio, Inc. has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. This resolves the deficiency notice previously issued by Nasdaq on October 19, 2023.
🚩 Red Flags
- Historical delisting risk (previously non-compliant with minimum bid requirement).
📋 Key Facts
- The Company received a letter from Nasdaq confirming it has regained compliance with Nasdaq Listing Rule 5450(a)(1).
- The minimum bid price matter is now considered closed.
- Compliance was achieved after the stock failed to maintain a $1.00 minimum price for 30 consecutive business days as of October 2023.